PKCα expression is a marker for breast cancer aggressiveness

Molecular Cancer

Research

Gry Kalstad Lønne¹  Louise Cornmark¹  Karin Jirström¹  Iris Omanovic Zahirovic¹  Christer Larsson¹  Göran Landberg¹ 

[1] Center for Molecular Pathology, Department of Laboratory Medicine, Lund University, Malmö University Hospital, SE- 205 02, Malmö, Sweden;

关键词: Breast Cancer;    Breast Cancer Cell;    T47D Cell;    Culture Breast Cancer Cell;    Primary Breast Cancer Tumor;   

DOI  :  10.1186/1476-4598-9-76

 received in 2009-11-03, accepted in 2010-04-14,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundProtein kinase C (PKC) isoforms are potential targets for breast cancer therapy. This study was designed to evaluate which PKC isoforms might be optimal targets for different breast cancer subtypes.ResultsIn two cohorts of primary breast cancers, PKCα levels correlated to estrogen and progesterone receptor negativity, tumor grade, and proliferative activity, whereas PKCδ and PKCε did not correlate to clinicopathological parameters. Patients with PKCα-positive tumors showed poorer survival than patients with PKCα-negative tumors independently of other factors. Cell line studies demonstrated that PKCα levels are high in MDA-MB-231 and absent in T47D cells which proliferated slower than other cell lines. Furthermore, PKCα silencing reduced proliferation of MDA-MB-231 cells. PKCα inhibition or downregulation also reduced cell migration in vitro.ConclusionsPKCα is a marker for poor prognosis of breast cancer and correlates to and is important for cell functions associated with breast cancer progression.

【 授权许可】

Unknown   
© Lønne et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.